Long-term effects of the liquid neuromodulator Alluzience® on ageing

Long-term effects of a liquid neuromodulating agent, Alluzience®, for the reduction of upper facial rhytdies and perceptions of age, health and wellbeing

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN43378293

Enrollment

Registered

2023-12-11

Start date

2023-10-01

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment and prevention of upper facial rhytdies including glabellar frown lines and crow’s feet. Skin and Connective Tissue Diseases

Interventions

One twin will be treated with Alluzience® and one will not treated. There will be no blinding of either patients or clinicians

twins will be allowed to decide which of them receives treatment and which is the control. This will be a multi-centre study with repeated intervention (every 4-6 months) and follow up over a period o

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Over the age of 21 years 2. Male or female 3. Identical twin; both twins must consent to participation in the study

Exclusion criteria

Exclusion criteria: 1. Pregnant or breastfeeding 2. Previous treatment with permanent/non-biodegradeable products to the upper face area. I.e. lifting threads or fat transfer (lipofilling) 3. Significant trauma and/ or surgery to upper face including fracture of skull/facial bones 4. Significant scarring of upper face 5. Neuromuscular disorder of the upper face including significant nerve palsy 6. Prescribed anticoagulant or have a bleeding disorder 7. Current or previous psychiatric illness (e.g. Psychosis, depression, anxiety) that could affect safety during the study 8. Participating in another scientific study within 30 days of starting treatment 9. Twins must not be receiving any other neuromodulator treatment for the reduction of upper facial rhytdies for the duration of the study

Design outcomes

Primary

Measure	Time frame
Assessed annually up to 5 years: 1. Assessor reported outcomes: improvement in Global Aesthetic Improvement Scale (GAIS) ratings following repeated treatments with Alluzience® 2. Patient reported outcomes: improvement in Global Aesthetic Improvement Scale (GAIS) ratings following repeated treatments with Alluzience®	—

Secondary

Measure	Time frame
Assessment of patients' emotional display, feelings about self, interpersonal communications and well-being (physical and psychological). This is undertaken via patient self-assessment questionnaires. Assessed annually up to 5 years.	—

Countries

England, United Kingdom

Contacts

Public ContactLara Watson

lara@acquisitionaesthetics.co.uk+44 7875425979

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026